Trial document

This study has been imported from without additional data checks.
drksid header


Trial Description

start of 1:1-Block title


Single-arm, Open-label, Single-center Phase II Study Evaluating the Efficacy and Safety of BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer After Failure of Treatment With Docetaxel or Ineligible for Treatment With Docetaxel

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym


end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial


end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

The purpose of this study is to find out what effects, good and/or bad, BIBW 2992 (Afatinib)
has on patients and their advanced prostate cancer which does not respond to hormone or
chemotherapy any more. Only patients with tumors which have an increased amounts of a
protein called HER2 on their cell surface will be included.

BIBW 2992 (Afatinib) is a drug which in advanced clinical testing in lung and breast cancer.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

This is a phase II study of BIBW 2992 (Afatinib) in patients with hormone and chemotherapy
(docetaxel) refractory, HER2 overexpressing prostate cancer. The exploratory study following
a two stage Gehan design. In the first stage 29 patients with be treated. Additional
patients will be recruited in a second stage depending on the number of responding patients
in the first step. Patients will receive BIBW 2992 (Afatinib) orally at a dose of 50 mg
daily. Response to therapy will be scored according to PSA values (Bubley criteria) and to
CT scans (RECIST criteria). Patients will be seen at 2 or 4 weeks intervals by a medical
professional while on the medication for toxicity assessment and physical examination.
Disease evaluations will occur at baseline and every 2 months thereafter. These evaluations
will include PSA testing and CT Scans (if appropriate).

end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00003995
  •   2012/10/26
  •   2011/03/17
  •   yes
  •   [---]*
  •   [---]*
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   NCT01320280  (
  •   1200.138  (Universitätsklinikum Hamburg-Eppendorf)
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   Refractory Cancer
  •   C61 -  Malignant neoplasm of prostate
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Drug: BIBW 2992 (Afatinib)
end of 1:N-Block interventions
start of 1:1-Block design


  •   Interventional
  •   [---]*
  •   Single arm study
  •   Open (masking not used)
  •   [---]*
  •   Uncontrolled/Single arm
  •   Treatment
  •   Single (group)
  •   II
  •   [---]*
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

- Objective PSA responses according to Bubley criteria; time frame: every two months; Bubley criteria see Bubley GJ, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999; 17: 3461-3467

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

- Objective response rate (ORR) based on Response Evaluation Criteria in Solid Tumours (RECIST 1.1); time frame: every 2 months
- Duration of PSA-response (Bubley criteria) or objective responses; time frame: every 2 months
- Safety; time frame: every 4 weeks; Description AEs according to CTC criteria

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

end of 1:n-Block recruitment locations
start of 1:1-Block recruitment


  •   [---]*
  •   2011/05/31
  •   29
  •   Multicenter trial
  •   [---]*
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Male
  •   18   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

- Patients must provide written informed consent

- Age ≥ 18 years

- Patients must have histological proven, hormone-refractory prostate cancer

- Patients must have failed prior therapy with docetaxel or must be ineligible for
treatment with docetaxel

- Patients must have ECOG performance status ≤ 2

- Patients must not have received any prior therapy targeting EGFR or HER2

- Patients must have adequate bone marrow, renal and hepatic function

- Patients must not have a history of severe heart disease

- Patients must not have had a myocardial infarction within the previous six months

- Patients must have normal left ventricular ejection fraction (LVEF ≥ normal limit of

- Patients must not have symptomatic brain or leptomeningeal metastatic disease

- Patients must have recovered from previous treatment-related adverse effects to
National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0
(CTCAE) grade ≤ 1

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

- Prior treatment with EGFR/HER2-targeted small molecules or antibodies, i.e.
trastuzumab and/or lapatinib

- Known pre-existing interstitial lung disease

- Radiotherapy, chemotherapy, hormone therapy (with the exception of GnRH agonists),
immunotherapy or surgery (other than biopsy) within 4 weeks prior to start of
treatment with BIBW2992. GnRH-agonists are allowed at the discretion of the

- Active brain metastases (defined as stable for < 4 weeks and/or symptomatic and/or
requiring changes of treatment with anticonvulsants or steroids within the past 4
weeks and/or leptomeningeal disease). Patients with known history of brain metastases
should undergo a baseline brain image to ensure that the disease is stable.

- Any other current malignancy or malignancy diagnosed within the past five (5) years
(other than non-melanomatous skin cancer).

- Significant or recent acute gastrointestinal disorders with diarrhoea as a major
symptom, e.g. Crohn's disease, malabsorption or CTC grade ≥ 2 diarrhoea of any

- History or presence of clinically relevant cardiovascular abnormalities such as
uncontrolled hypertension, congestive heart failure NYHA classification of 3,
unstable angina or poorly controlled arrhythmia. Myocardial infarction within 6
months prior to randomisation.

- Cardiac left ventricular function with resting ejection fraction of less than 50%.

- Any other concomitant serious illness or organ system dysfunction which in the
opinion of the investigator would either compromise patient's safety or interfere
with the evaluation of the safety of the test drug.

- Absolute neutrophil count (ANC) < 1500 / mm³.

- Platelet count < 75,000 / mm³

- Calculated creatinine clearance < 60 ml / min (using Cockcroft-Gault formula for GFR
estimate) or serum creatinine > 1.5 times upper limit of normal.

- Uncontrolled hypercalcemia

- Patients unable to comply with the protocol.

- Known hepatitis B infection, known hepatitis C infection or known HIV carrier.

- Known or suspected active drug or alcohol abuse.

- Requirement for treatment with any of the prohibited concomitant medications

- Any contraindications for therapy with BIBW 2992.

- Known hypersensitivity to BIBW 2992.

- Use of any investigational drug within 4 weeks of start of treatment

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses


  • start of 1:1-Block address primary-sponsor
    • Universitätsklinikum Hamburg-Eppendorf
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address other
    • Boehringer Ingelheim
    end of 1:1-Block address other
    start of 1:1-Block address contact other
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact other
  • start of 1:1-Block address scientific-contact
    • Universitätsklinikum Hamburg-Eppendorf
    • Walter Fiedler, M.D: 
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Universitätsklinikum Hamburg-Eppendorf
    • Walter Fiedler, M.D: 
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state


  •   Recruiting complete, follow-up complete
  •   2012/11/01
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  •   Minner S, Jessen B, Stiedenroth L, Burandt E, Köllermann J, Mirlacher M, Erbersdobler A, Eichelberg C, Fisch M, Brümmendorf TH, Bokemeyer C, Simon R, Steuber T, Graefen M, Huland H, Sauter G, Schlomm T. Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer. Clin Cancer Res. 2010 Mar 1;16(5):1553-60. doi: 10.1158/1078-0432.CCR-09-2546. Epub 2010 Feb 23.; 20179235
  •   Yap TA, Vidal L, Adam J, Stephens P, Spicer J, Shaw H, Ang J, Temple G, Bell S, Shahidi M, Uttenreuther-Fischer M, Stopfer P, Futreal A, Calvert H, de Bono JS, Plummer R. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol. 2010 Sep 1;28(25):3965-72. doi: 10.1200/JCO.2009.26.7278. Epub 2010 Aug 2.; 20679611
end of 1:n-Block publications
The parameters in and DRKS are not identical. Therefore the data import from required adjustments. For full details please see the DRKS FAQs .
  •   6
  •   2016/01/14

* This entry means the parameter is not applicable or has not been set.